After increasing his drug pricing-related complaints, the HELP committee chair opposed Bertagnolli becoming NIH director, but a bipartisan group of senators voted 15-6 in favor of moving her nomination to the full Senate.
The pharma industry’s relationship with the National Institutes of Health does not appear to be changing significantly should director nominee Monica Bertagnolli be confirmed, even though the agency still may be linked to drug pricing issues.
Bertagnolli gained bipartisan support from the Senate Health, Education, Labor and Pensions Committee to move her nomination to the full...
Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.
Senate HELP Committee chair Sanders trying to broker a deal between Novo Nordisk and the major pharmacy benefit managers that will lead to lower list prices.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
An effort to change the US Food and Drug Administration’s conclusion that its obesity treatment candidate retatrutide is a drug and not a biologic could give the product more time with unrestricted pricing in Medicare, among other benefits.
Pharmacy benefit manager sues Federal Trade Commission claiming chair Khan has orchestrated a campaign against PBMs that is not based in fact.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.
